Isomorphic Labs 融资 50 亿美元,专注 AI 制药
Demis Hassabis 的 Isomorphic Labs 拿下 50 亿美元 A 轮,Greenoaks、Sequoia、a16z 和 Alphabet 都在名单里。他们的 AI 药物引擎在癌症和免疫学上已经有积极的临床前数据,马上要进临床试验。关注 AI 制药落地速度的话,这条信息量很大。
Demis Hassabis 旗下的 Isomorphic Labs 完成 50 亿美元 A 轮融资,由 Greenoaks 和 Sequoia 联合领投,a16z 与 Alphabet 参与投资。
公司的药物设计引擎已在癌症和免疫学领域获得积极的临床前结果,下一步将进入临床试验阶段。
Isomorphic Labs 从 Google DeepMind 拆分而来,核心思路是用 AI 模型预测蛋白质结构与分子相互作用来设计药物。50 亿美元规模在 AI 制药领域属于大额融资,说明投资方对 AlphaFold 技术路线商业化前景的判断。
Super cool to see that Demis Hassabis is going all in on AI designed medicine.
He just raised $5B in a series A co lead by Greenoaks and Sequoia with a16z and Alphabet in it for Isomorphic labs.
And even more good news: The company says its drug design engine is already getting positive preclinical results in cancer and immunology. And clinical trials are next.
I love to read that.
This report is categorized under AITOP's "Industry" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Key entities and technical topics under continuous tracking include Isomorphic Labs, Demis Hassabis, AI drug discovery, drug design.
Source attribution: curated from kimmonismus (@kimmonismus).